Anuroop Packaging Limited

CIN: L25202MH1995PLC093625

REGISTERED. OFFICE – 105, AMBISTE BUDRUK, POST KHANIVALI, TAULKA – WADA, PALGHAR - 421303.

CORPORATE OFFICE – 607, 6TH FLOOR, IJMIMA COMPLEX, OFF. LINK ROAD, MALAD WEST, MUMBAI – 400064.

Contact No.: 022-49240182/83 Email ID: info@anurooppackaging.com

27th December, 2021.

BSE Limited

Corporate Relations Department, 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Mumbai -400 001, India Scrip code: 532454.

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Advertisement in newspapers in respect of certain matters relating to rights issue of equity shares of the Company ("Rights Issue")

Dear Sir/Ma'am,

We enclose copies of advertisement issued by the Company on December 24, 2021, in respect of certain matters relating to rights issue of equity shares of the Company, in all editions of (i) Business Standard (English newspaper); and (ii) Navshakti (Marathi newspaper).

Kindly take the above on record.

Thanking you, Yours faithfully,

For Anuroop Packaging Limited

Akash Amarnath Sharma

Mh. h.m.

Director

DIN: 06389102

Encl: as above

A pipeline in the slow lane

The Indian Gas Exchange, which opened for business last year, is waiting for regulatory reforms to achieve its mandate of expanding access to the fuel



New Delhi, 23 December

 $ndian\,Gas\,Exchange\,(IGX), a\,conduit\,to$ expanding the country's access to gas, is hobbling along, waiting for policy and regulatory reforms from New Delhi to move into a fast lane. An exchange is typically a place where commodities or shares are traded freely enabling price discovery. But that's still not the case with IGX, a key component of India's strategy to vault natural gas use to 15 per cent of our energy mix by 2030 from 6 per cent now.

Traded volumes on IGX totalled 785 billion British Thermal Units (Btu) last month at an average price of \$24.8 per mBtu compared with 3 billion Btu traded in September 2020 at an average price of \$5.5 per mBtu two months after the exchange opened for business last year, according to IGX data. Trading may expand from January next year once the exchange adds a new contract, the first for domestic gas supplies, said Rajesh K Mediratta, CEO, IGX.

But record spot LNG prices make the fuel unviable for a price-sensitive Indian market. "It is not good for the sector to have such high prices over a sustained period," Mediratta said. "It will lead to demand destruction and consumers will not shift to cleaner fuels like gas," he added. India's gas use dropped by 2.4 per cent last month from a vear earlier. Record spot LNG rates have put off Indian consumers, a Petronet LNG official said, which means lower interest for regassified LNG on IGX.


Gas trades on IGX are a fraction of what India consumes. India consumed 175 mil-So IGX delivered around 0.4 per cent of the volumes that India consumed in November. Let's compare that to how much the India power consumption.

GAS TRADES ON IGX

4onth	Trades	Price
Nov-21	785	\$24.80
ep-20	3	\$5.50
ource: IGX		

DIP IN USE

(in billion cubic metres)



ural gas and cooking gas by building infratrade. IGX started operations in June 2020, lion cubic metres a day (m³/d) of gas on an amid the pandemic, as a gas trading plataverage in FY2020 before the Covid-19 pan-form. The IGX traded contracts offered buydemic, according to the oil and gas ministry. ers options to evaluate exchange-traded That equates to 184 trillion Btu for a month. rates versus imported LNG and prices of fuel offered via tenders

when less than 0.5 per cent of volumes are electricity sector. Fuel transport charges Energy Exchange (IEX), IGX's parent, traded traded. Gastrading platforms typically come are calculated based on a few zones and in the electricity market. IEX realised 6.79 about where domestic deposits are abunneed to be optimised. Differing state taxes billion units (BU) cleared volume in dant or if the place acts as a hub for trade, on gas and Delhi's inability to have a single November. Power consumption during the which is not the case for IGX or India. goods and services tax charge is also hurting period was 100.4 BU, according to the Domestic production is still insufficient to trades. The lack of a state mandate to allot National Load Despatch Centre. That means meet growing demand, keeping India reliant gas to the IGX is also slowing trades, unlike IEX, which started operations in 2008, on imported LNG to meet over half its needs. in the power sector where power plants accounted for around 7 per cent of India's That leaves IGX dependent on the govern- offer 15 per cent of their output to be traded ment for market-friendly measures.

IGX was hobbled from the start for lack of adequate physical pipeline infrastructure, multiple pipeline operators and systems, and price controls on the fuel. Domestic gas was unavailable for trades leaving it dependent on some regassified LNG as most of the imported LNG is tied up in term supply contracts.

New Delhi, meanwhile, is delaying gas price reforms. The government controls both fuel prices and allocations of natural gas. Rates are set biannually and are one of the lowest in the world. The ceiling price of gas from deep-water, ultra-deep-water, hightemperature and high-pressure areas is \$6.13/mBtu on a gross calorific basis for the October-March period, while the price of conventional gas is \$2.90/mBtu, well below the traded rates on IGX, \$35/mBtu spot LNG levels in Asia and less than the \$10/mBtu India pays for Qatari term LNG supplies. Domestic prices are based on weighted average prices at the US Henry Hub, the UK's National Balancing Point and Canadian and Russian prices, with a lag of one quarter.

The lack of an extensive gas distribution network also hurts volumes because IGX is a delivery platform and is barred from offering paper contracts or derivative trades, leaving it reliant on pipelines for physical deliveries of gas. India's pipeline infrastructure at around 16,000 km is inadequate and concentrated in the western region. Trunk lines are now being built in the east and northeast of India and southern region, which should more than double the existing network, along with distribution networks to send the gas to consumers.

There have been delays in approvals as well, crimping IGX's ability to increase volumes. Producers are permitted to sell as much as 500 million m³ or 10 per cent of annual output from their areas, whichever is higher, through IGX or other exchanges approved by sector regulator the Petroleum and Natural Gas Regulatory Board (PNGRB), the government said in August. Staffing issues at PNGRB have delayed approvals.

Once IGX secures permission from PNGRB, it plans to offer a separate contract for domestic supplies because gas supplied from unconventional areas has a price cap. Bidders must make offers equal to or below the cap. IGX is launching a separate contract for unconventional area gas because its existing contracts based on imported LNG allow pricing freedom and settlement of trades based on exchange prices (the government does not control LNG prices). Gas found in unconventional areas include methane trapped within tight pore spaces The IGX was supported by former oil like shale and coal seam beds or fuel trapped minister Dharmendra Pradhan, who was in ice on the sea floor such as gas hydrates. instrumental in expanding coverage of nat- Natural gas is referred to as "conventional" when it can be extracted from the earth structure and enabling intermediaries for either through naturally occurring pressure, or pumping mechanisms.

India also needs to appoint an independent system operator to enable efficient delivery of the fuel. IGX staff currently approach different operators to facilitate deliveries of the fuel instead of a single But you cannot aspire for price discovery agency — something that is in place in the on the electricity exchange.

'2021 saw greater collaboration among pharma, govt, academia'

This was a landmark year for the Indian pharma sector, which churned out new vaccines, collaborated for new drugs and ramped up supplies of key products. **SUDARSHAN JAIN**, secretary general, Indian Pharmaceutical Alliance (IPA), speaks to Sohini Das about the trends that marked 2021 and what lies ahead for the Indian drug industry. Edited excerpts.

SUDARSHAN JAIN

Secretary general, Indian

What were the key trends that dominated

the Indian pharma industry in 2021? Every adversity offers opportunity. The Covid-19 pandemic brought healthcare to the centre-stage. One big trend in 2021 was collaboration - among government, industry and academia. Bureaucrats were most solution-oriented. (and focused on) what can be done, and done fast, Secondly. we realised the importance of self-reliance. In the initial days of Covid, we did not have enough PPE kits, testing kits, ventilators etc. We have had to create our own healthcare security. We also saw that regulatory processes got streamlined. Increased thrust on research and development was another key area that emerged in 2021. The Indian pharmaceutical industry also focused on the safety of employment and employees. Digitalisation and the speed at which it happened was a major change — we can connect with the USFDA (United States Food and Drug Administration) anytime and with stakeholders across the globe. Telemedicine and awareness about health-

care have grown in leaps and bounds. Imagine, a pulse oximeter has reached homes and people are now consciously monitoring their health.

Howhasthepandemic changed the way the pharma industry works?

There has been a fundamental change in the mindset; it is now more collaborative. In earlier times, if the sales team gave a forecast to the production team. and it went wrong, the latter would most certainly get back and ask why a wrong forecast was given. But now we see things are quite different, more collaborative; there is more understanding of the broader uncertainties etc. Silos within the organisations have broken. If demand for a particular product suddenly shoots up, how quickly the production team can gear up to ramp



up production — the focus is more on adapting to a more dynamic environment.

There has been an increased trend of voluntary licensing — remdesivir being a case in point. We should leverage this further in the future. Digitisation helped in quality control and assurance, supply chain operations, easing of clinical trials.

What kind of recommendations have you put forward to the government to streamline regulatory

processes?

We have asked for streamlining things on the regulatory side and making processes simpler. For example, we have suggested that every proposal (from the industry for drug approval or clinical trials) should be treated like a

project. A project management system needs to be brought in — once someone applies, someone at the regulator's end has to monitor it: there have to be clear timelines. In the US, there are clear standard operating procedures (SoPs). We need to create such SoPs in India, too. We also need a single point of contact instead of multiple points, and also see that duplications are avoided. These will bring about fundamental changes for the benefit of the patient, while ensuring safety guidelines are maintained. All these recommendations have been made.

Howlong till we are no longer dependent on China for bulk drugs?

Diversified supply chain is a fundamental need. India lost that advantage in the 1980s. We have to revive that, but it won't happen in a year's time. China has already built that advantage, and their cost of production is already 25-30 per cent lower. This government has taken steps at a policy level. Still, it will take three to five years until we are self-reliant in active pharmaceutical ingredients (APIs). There will be price volatility in the meantime, and we have to be prepared for it.

It is not that we do not have a price advantage at all. We have to go item by item, and build capacities to make fermentationbased APIs etc. We have to slowly build a diversified supply chain for APIs.

Anybasic R&D by Indian pharma for Covid-19 drugs?

At present, it is only vaccines where we have done some original research mRNA, DNA. There is nothing in the public domain so far on basic research for Covid-19 drugs by Indian pharma yet. There are talks of collaborations with global majors. We already have tie-ups for molnupiravir (antiviral medication used to treat Covid-19) in place.

2022and beyond—what is the outlook?

There are a few focus areas. We know that 67 per cent of the world market for drugs comes from patented products. India's presence in that area is very less. We have to focus on drug discovery - some companies like Zydus Cadila, Sun Pharma, Lupin and Cipla are increasing their research expenditure, Last year, Indian pharmaceutical turnover (including exports) was about \$44 billion, and we are targeting \$130 billion in the next few years. We have to not only be at the top in terms of volume, but also be among the top five in terms of value. At the moment, we are 13th in terms of value. Unless we do basic research, come out with new molecules, we cannot reach that future.

NEWSMAKER / PRADEEP KUMAR RAWAT / INDIAN AMBASSADOR TO CHINA

Himalayan challenge

New Delhi, 23 December

China has dominated much of Pradeep Kumar Rawat's working life since he joined the Indian Foreign Service in 1990. Not only does he speak Mandarin fluently but has also spent almost 20 years studying China in one or the other capacity. He will move to Beijing from the Netherlands, but even during his short tenure in the latter country, he made it a point to visit the South Asian & Tibetan Studies institute at Leiden University. This is a big leap for a boy who started life believing he would become an engineer - Rawat studied mechanical engineering at the National Institute of Technology, Kurukshetra, from 1982 to '87. When not addressing China, Rawat has served in Indonesia and Timor-Leste as ambassador. He taught briefly at the South Asian University, Delhi. In Beijing, Rawat replaces Vikram Misri

saw the military build-up and also helped — Meenakshi Lekhi and Rahul Kaswan defuse it through negotiation. Bilateral ties participated in the virtual swearing-in cereare arguably at their lowest point. Rawat is mony of Taiwan President Tsai Ing-wen. in a position to judge because he's seen bet- Although in the winter session of Parliamter days as well: He was posted in Hong ent, Minister of State for External Affairs ical and economic changes China is under-Kong, and then in Beijing, between 1992 and V Muraleedharan made it clear that India going. Analysts say the resolution passed 1997 through the tumultuous days of the does not have formal diplomatic relations after the Sixth Plenum of the Communist handing over of Hong Kong by Britain back with Taiwan, and the two sides have only Party's 19th Central Committee (the full text to China, returning to work in the East Asia trade and people-to-people ties, even the came out on November 16) shows that Division for three years. A second four-year most innocuous diplomatic moves are wat- Xi Jinping still faces constraints on his ability term in Beijing in 2003, initially as counsellor ched closely by Beijing, which views Taiwan to impose sweeping or controversial policy and then as the deputy chief of mission, fol- as its province, while the island authorities changes and suggests that his influence is lowed. This coincided with two break-maintain that it is an autonomous country. preeminent but not absolute, and consensus throughs on the boundary question with meters and guiding principles in 2005.



India's envoys to Beijing have rarely, if ever, had the experience of serving in Taipei as well. India is cautiously scaling up its relations with Taiwan, much to the irritation of China

who had a three-year stint and possibly not serving as head of the India-Taipei Associa single day without challenges. In June last ation, the de facto ambassador, for the next year, the Galwan clash that saw 20 Indian four years. This makes his career profile soldiers killed was the culmination of border quite unique: India's envoys to Beijing have tension that had been building up for more rarely, if ever, had the experience of serving summit, specifically on coal; and India's retthan three years from the 73-day stand-off in Taipei as well. India is cautiously scaling at Doklam in 2017. As joint secretary (East up its relations with Taiwan, much to the Asia) from 2014 to 2017, it was Rawat who irritation of China. Earlier this year, two MPs

Misri's send-off and the reaction in Chinthe appointment of special representatives ese media to Rawat's appointment suggest important than commonly believed. Could in 2003 and an agreement on political parathetide in Sino-Indian ties might be turning. this push Xi to more ultra-nationalist posi-They could be straws in the wind. But during tions with one target being India? Rawat will He moved to Taiwan two years later, a virtual farewell to Misri, Chinese Foreign have to steer the course.

Minister Wang Yi said: "China and India are two ancient civilisations, two emerging economies, and neighbours that cannot be moved away. When we build mutual trust, even the Himalayas cannot stop us from friendly exchanges. Without mutual trust, it is difficult to bring the two sides together, even if there are no mountains in the way. China and India should become partners and friends. The important consensus that China and India should not be a threat to each other, but an opportunity for each other's development, which reached by the leaders of the two countries, should continue to be adhered to [sic]." Misri responded: "Although there are still dark clouds in the sky, we have already seen the silver lining in the dark clouds.

Local media is quite approving of India's choice of envoy. While noting that individuals have a limited role in diplomacy, Wang Dehua, from the Shanghai Municipal Centre for International Studies, was quoted as saying that despite the impasse on border talks. Rawat's appointment was a good sign. And there were others, too: Sino-Indian cooperation during the Glasgow climate change icence over calls for an international investigation into the origins of Covid-19. China views this "as a big favour" by India, Wang was quoted as saying. And a new ambassador who was fluent in Mandarin would ease relations further.

Of course, this does not factor in the politand factional compromise remain more

Our Company was originally incorporated as "Anuroop Packaging Private Limited" at Mumbai as a private limited company under the Companies Act. 1956 vide Certificate of Incorporation dated October 13, 1995 bearing Corporate Identification Number 93625 issued by the Registrar of Companies, Mumbai. Subsequently, our company got converted to a public limited company pursuant to a special resolution passed by the shareholders of our company at their meeting held on May 27, 2017 and fresh Certificate of Incorporation consequent upon conversion was issue by Registrar of Companies, Mumbai on July 02, 2017 in the name of "Anuroop Packaging Limited". For details of change in name and registered office of our Company, see "General Information" on page 29 of the letter of offer dated November

Registered Office: Ambiste (BK), Post Khani Tal Wada, Thane - 421303, Maharashtra, India | Tel: 022 – 49240183 Contact Person: Shah Pooja Ketan, Company Secretary and Compliance Officer info@anurooppackaging.com | Website: www.anurooppackaging.com Corporate Identity Number: L25202MH1995PLC093625 OUR PROMOTERS: MR. AMARNATH MATADIN SHARMA MR. AKASH AMARNATH SHARMA,

MR. AKSHAY AMARNATH SHARMA AND AMARNATH SHARMA HUF

RIGHT ISSUE OF UPTO 30,64,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES" OR "RIGHTS EQUITY SHARES) OF OUR COMPANY FOR CASH AT A PRICE OF ₹13.00 PER RIGHTS EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹3.00 PER RIGHTS EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING UP TO ₹ 398.37 LAKH ("THE ISSUE") ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 2 (TWO) RIGHTS EQUITY SHARES FOR EVERY 5 (FIVE) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY ON THE RECORD DATE, THAT IS FRIDAY, IOVEMBER 05, 2021 (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" ON PAGE 81 OF THE LETTER OF OFFER

BASIS OF ALLOTMENT

The Board of Directors of our Company thanks all Investors for their response to the Issue, which opened for subscription on Monday, November 22, 2021 and closed on Tuesday, December 14, 2021 and the last date for On Market Renunciation of Rights Entitlements was Wednesday, December 01, 2021. Out of the total 152 Applications for 32,50,000 Rights Equity Shares (including 21 Applications for 6,70,000 Rights Equity Shares through R-WAP), 99 Applications for 2,48,000 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 53 for 30.02.000 Rights Equity Shares, which was 100.00% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer and the Basis of Allotment finalized on **Tuesday, December 21, 2021** in consultation with BSE Limited ("BSE"), the Designated Stock Exchange and the Registrar to the Issue, the Board of Directors of the Company has, on **Tuesday, December 21, 2021**, approved the allotment of **30,02,000** fully paid up Rights Equity Shares to the successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications (including R-WAP Applications) after technical rejections have been considered

*Applications includes 2 partially accepted case.

. The breakup of valid applications received through ASBA and R-WAP (after technical rejections) is given below:

Applicants	Number of valid applications received	accepted and allotted against Rights Entitlement (A)	and allotted against Additional Rights Equity Shares applied (B)	Shares accepted and allotted (A+B)
Eligible Equity Shareholders	41	9,98,000	1,504,000	2,502,000
Renouncees	12	4,92,000	8,000	500,000
Total	53	14,90,000	1,512,000	3,002,000

*Applications includes 2 partially accepted case

2. Information regarding total Applications received (including ASBA and R-WAP Application):

Catagory	Applications Received		Equity Shares Applied for			Equity Shares allotted		
Category	Number	%	Number	Value (₹)	%	Number	Value (₹)	%
Shareholders	140	92.11%	2,750,000	35,698,002.00	84.60%	2,502,000	32,526,000.00	83.34%
Renouncees	12	7.89%	500,000	6,500,000.00	15.40%	500,000	6,500,000.00	16.66%
Total	152	100.00%	3,250,000	42,198,002.00	100.00%	3,002,000	39,026,000.00	100.00%

nformation for Allotment/refund/rejected cases: The dispatch of Allotment Advice cum Refund Intimation to the investors, as applicable, has been completed on December 22, 2021. The instructions for unblocking of funds in case of ASBA Applications were issued to SCSBs on December 22, 2021, and for refund of funds through NACH/NEFT/RTGS/direct credit were issued to ICICI Bank Limited, the Banker to the Issue, on December 22,2021. The listing application was executed with BSE on December 21, 2021. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of Allotment in dematerialized form has been completed on December 23, 2021. For further details, see "Terms of the Issue – Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 102 of the Letter of Offer. The trading in fully paid-up Equity Shares issued in the Rights Issue shall commence on BSE under a same ISIN - INE490Z01012, as the existing equity shares, upon receipt of trading permission. The trading is expected to commence on or about December 27, 2021. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DILZ/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN THE DEMATERIALISATION FORM. DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that the submission of the Letter of Offer to SEBI should not in any way deemed or construed that he Letter of Offer has been cleared or approved by SEBI. The investors are advised to refer to the Letter of Offer for the full text as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of SEBI" on page 76 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the letter of offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of BSE as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 76 of the Letter of Offer.

Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS

PROSPECTS OF THE COMPANY The details of the allotment made has been hosted on the website of the Registrar to the Issue. KFin Technologies Private Limited at Website: www.kfintech.com

MFINTECH

KFin Technologies Private Limited (Formerly known as KARVY FINTECH PRIVATE LIMITED)

Selenium Tower-B, Plot No-31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi 500032, Telangana, India | Tel: +91 40 6716 2222 Email: Anuroop.rights@kfintech.com | Website: www.kfintech.com

REGISTRAR TO THE ISSUE

Investor Grievance E-mail: einward.ris@kfintech.com Contact Person: M Murali Krishna | SEBI Registration No.: INR000000221

Anuroop Packaging Limited

Ms. Shah Pooia Ketan Registered Office: Ambiste (BK), Post Khani Tal Wada, Thane - 421303, Maharashtra, India. | **Telephone:** 022 - 4924 0183

COMPANY SECRETARY AND COMPLIANCE OFFICER

E-mail: info@anurooppackaging.com Website: www.anurooppackaging.com

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process or R-WAP process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address of the Applicant, contact number(s), E-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process) or amount debited (in case of R-WAP process), ASBA Account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process)), and copy of the e-acknowledgement (in case of R-WAP process). For details on the ASBA process and R-WAP process, see "Terms of the Issue" on page 81 of Letter of Offer

For, Anuroop Packaging Limited

Place : Mumbai Date: December 23, 2021

Company Secretary and Compliance Officer

Disclaimer: Our Company has filed a Letter of Offer with the Securities and Exchange Board of India and the Stock Exchanges. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchanges where the Equity Shares are listed i.e. BSE at www.bseindia.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 17 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

एपीएमसी मार्केट वाशी तुर्भे शाखा दुकान क्र. १००१ ते १००४, २००१ ते २००२ आणि ३००१ ते ३००२, बी विंग, मयुरेश ट्रेड सेंटर (सिटीमॉल), प्लॉट क्र ४, सेक्टर : 027-2028 2828

कर्जा सूचना सं. क्र. बीओआय एपीएमसी/एडीव्ही/जीके/१४३

ज्याअर्थी, निम्नस्वाक्षरीकार बैंक ऑफ इंडियाचे प्राधिकृत अधिकारी या नात्याने सिक्युरिटायझेशन ऑण्ड रिकन्स्ट्रक्शन ऑफ फायनाव्याअल ॲसेटस ऑण्ड एन्फोर्समेंट ऑफ सिक्युरीटी इंटरेस्ट ऑक्ट, २००२ आणि कलम १३(१२) सिक्युरीटी इंटरेस्ट ्एन्फोर्समेंट) रूल्स, २००२ सहवाचता नियम ३ अन्वये प्राप्त अधिकारांचा वापर करून दिनांक **१६-०९-२०२१** रोजी मागर्ण . सूचना जारी करून कर्जदार **श्री. तरण बिजेन लेत** यांस सूचनेतील नमूद रक्कम रु. २०,५६,९९५.**६६/** – अ**धिक व्या**ज ्राच्या जान करण जाना का साम निर्माण का स्वाप्त का स्वाप्त का किया है। अपने का स्वाप्त का स्वाप्त का स्वाप्त का (पावदात वीस लाख छप्पन हजार नजरों पंच्यात्रव आणि सव्वीस पैसे अधिक १७.०९.२०२१ पासूनचे व्याज) या रकमेची परतफेड सदर सूचना प्राप्तीच्या ६० दिवसांत करण्यात सांगितले होते.

रकमेची परतफेड करण्यास कर्जदार असमर्थ ठरल्याने, कर्जदार आणि सर्वसामान्य जनतेस यादारे सचना देण्यात येते की. म्नस्वाक्षरीकारांनी खाली वर्णन करण्यात आलेल्या मिळकतीचा सदर सिक्युरिटी इंटरेस्ट (एन्फोर्समेंट) रूल्स, २००२ च्य नियम ८ सहवाचता सद्र ॲक्टचे कलम १३ उप-कलम (४) अन्वये प्राप्त अधिकारांचा वापर करुन २२ डिसेंबर, २०२१ रोजी

आणि सदर मिळकतीशी करण्यात आलेला कोणताही व्यवहार हा बँक ऑफ इंडिया करीता रक्कम रु. २०,५६,९९५.६६/-**अधिक** १७.०९.२०२१ पासूनचे त्यावरील व्याजाच्या भाराअधीन राहील. गरण मत्ताच्या विमोचनाकरिता उपलब्ध वेळेत ॲक्टचे कलम १३ चे उप-कलम (८) च्या तरतुदीनुसार कर्जदारांचे लक्ष

स्थावर मिळकतीचे वर्णन

ा. क्र. ८७, हिस्सा क्र. ०२ गाव महोदर, तालुका पनवेल, जि. रायगड येथील अरिहंत अमिषा अशा नावाच्या सोसायटीमधीत विंग बी-४ मधील. १ला मजला येथे स्थित निवासी फ्लॅट क्र. १०४ सीमाबद्धता ; **उत्तरेला** – लगतचा फ्लॅट क्र. १०३, **दक्षिणेला** – डक्ट, **पूर्वेला** – इमारतीचे प्रवेशद्वार, **पश्चिमेला** – प्रवेशद्वा

पाधिकत अधिकारी, बँक ऑफ इंडिया ठिकाण: पनवेल, जिल्हा रायगड

कंपनीचे नाव: जी. एम. ब्रेव्हरिज लि., कंपनीचे नोंदणी कार्यालय: गणेश निवास, एस. व्ही. सावरकर मार्ग, प्रभादेवी, मुंबई- ४०००२५, महाराष्ट्र

सूचना याद्वारे देण्यात येते की, कंपनीच्या खालील नमुदर सिक्युरिटीज करिताचे प्रमाणपत्र हे हरवले /गहाळ झाले आहे आणि सदर सिक्युरिटीजच्या धारकांनी कंपनीकडे अर्ज केला

कोणाही व्यक्तीचा सदर सिक्युरिटीजच्या संदर्भात दावा असल्यास सदर तारखेपासून १५ दिवसात तिच्या नोंदणीकृत कार्यालयात कंपनीकडे असा दावा दाखल करणे आवश्यक आहे, अन्यथा कंपनी पुँढील कोणतीही सूचना न देता प्रतिलिपी शेअर प्रमाणपत्र जारी करण्याची कार्यवाही करेल

वारकाचनाच	काालजा	ासक्यु।रटाजवा	।सक्यु।स्टाजवा	ାସାକ୍ୟ ୨ନ.	яніччя
	क्र.	प्रकार	संख्या		क्र.
		आणि दर्शनी मूल्य			
प्रविणा के. शाह	पी०१०७२	दर्शनी मूल्य-१०/-	900	५९०२२०१ ते ५९०२३००	३३५०३
			२५	११६७७६०९ ते ११६७७६३३	७००९९
			38	१८२४९००८ ते १८२४९०३८	७३४१७
ठिकाण : मंब	र्ड			धारक	- ाचे नाव

Aditya Birla Sun Life **Mutual Fund**



Aditya Birla Sun Life AMC Limited(Investment Manager for Aditya Birla Sun Life Mutual Fund) Registered Office: One World Center, Tower 1, 17th Floor, Jupiter Mills, Senapati Bapa Marg, Elphinstone Road, Mumbai - 400 013. Tel.: 4356 8000. Fax: 4356 8110/8111. CIN: L65991MH1994PLC080811

दिनांक: २४.१२.२०२१

Addendum No. 51/2021

Notice-cum-Addendum to the Scheme Information Document ("SID") and Key Information Memorandum ("KIM") of Aditya Birla Sun Life Overnight Fund and Aditya Birla Sun Life **Liquid Fund**

I.Introduction of Additional plans under Aditya Birla Sun Life Overnight Fund for deployment of unclaimed amounts:

NOTICE IS HEREBY GIVEN THAT, pursuant to SEBI Circulars no. SEBI/HO/IMD/IMD-II DOF3/P/CIR/2021/608 dated July 30, 2021, SEBI/HO/IMD/DF2/CIR/P/2016/37 dated February 25, 2016 and SEBI / IMD / CIR No 14 / 187175/ 2009 dated December 15, 2009, the Board of Directors of Aditya Birla Sun Life AMC Limited, Investment Manager for Aditya Birla Sun Life Mutual Fund and Aditya Birla Sun Life Trustee Private Limited, Trustees to Aditya Birla Sun Life Mutual Fund have approved introduction of additional plans under Aditya Birla Sun Life Overnight Fund, an open ended debt scheme investing in overnight securities. A relatively low interest rate risk and relatively low credit risk. ("the Scheme") for deployment of unclaimed redemption and IDCW amounts with effect from Sunday, December 26, 2021.

- 1. The plans under the Scheme shall have the following nomenclature:
 - Aditya Birla Sun Life Overnight Fund Unclaimed IDCW Upto 3 Years
 - Aditya Birla Sun Life Overnight Fund Unclaimed IDCW Greater than 3 Years
 - Aditya Birla Sun Life Overnight Fund Unclaimed Redemptions Upto 3 Years
 - · Aditya Birla Sun Life Overnight Fund Unclaimed Redemptions Greater than 3 Years *IDCW - Income Distribution cum Capital Withdrawal
- 2. Investors who claim the unclaimed amount during a period of 3 years from the date of investment in unclaimed plans shall be paid initial unclaimed amount along with the income earned on its
- 3. Investors claiming these amounts after 3 years from the date of investment in unclaimed plans, shall be paid initial unclaimed amount along with income earned on its deployment till the end of third year of investment. After the third year, the income earned on such unclaimed amounts shall be used for the purpose of investor education.
- 4. The aforesaid plans under the Scheme shall not be available for subscription / switch-in by the
- 5. No exit load shall be charged in aforesaid plans.
- 6. The Total Expense Ratio of the aforesaid plans shall be capped at 50 basis points.
- 7. Minimum initial / additional subscription amount shall not be applicable to new plans.
- 8. Scheme Characteristics: Investment Objective, Asset Allocation Pattern, Investment Strategy, Risk Factors Facilities offered by the Scheme and other terms & conditions shall remain same as that for the existing plans under the Scheme (except for provisions mentioned above).
- 9. Investors can submit a separate request for redemption / switch from any of the aforesaid plans. Investors request will be treated as "All units" only and the amount as available in all the aforesaid plans shall be redeemed / switched. No partial redemption / switch will be allowed for investors.

The unclaimed redemption and IDCW amounts held in Aditya Birla Sun Life Liquid Fund, an open ended Liquid Scheme. A relatively low interest rate risk and moderate credit risk, will be switched to unclaimed Plans of Aditya Birla Sun Life Overnight Fund in the following manner after the effective

Sr. No.	Switch-out from Aditya Birla Sun Life Liquid Fund – Unclaimed Plans	Switch-in to Aditya Birla Sun Life Overnight Fund – Unclaimed Plans
1.	Aditya Birla Sun Life Liquid Fund - Unclaimed IDCW - 3 Months to 3 Years	Aditya Birla Sun Life Overnight Fund - Unclaimed IDCW - Upto 3 Years
2.	Aditya Birla Sun Life Liquid Fund - Unclaimed IDCW - Greater than 3 Years	Aditya Birla Sun Life Overnight Fund - Unclaimed IDCW - Greater than 3 Years
3.	Aditya Birla Sun Life Liquid Fund - Unclaimed Redemptions - 3 Months to 3 Years	Aditya Birla Sun Life Overnight Fund - Unclaimed Redemptions - Upto 3 Years
4.	Aditya Birla Sun Life Liquid Fund - Unclaimed Redemptions - Greater than 3 Years	Aditya Birla Sun Life Overnight Fund - Unclaimed Redemptions - Greater than 3 Years

The proposed switch herein would be taxable in the hands of the investor as per the applicable provisions of the Income Tax Act, 1961 ("the Act"). In case of NRI investors, TDS shall be deducted in accordance with the applicable provisions of the Act. In view of individual nature of tax implications, investors are advised to consult their tax advisors. For details on tax implications, please refer to the SID of the Scheme and Statement of Additional Information available with our ISCs and on our website https://mutualfund.adityabirlacapital.com.

II.Discontinuation of Unclaimed Plans of Aditya Birla Sun Life Liquid Fund:

The unclaimed plans of Aditya Birla Sun Life Liquid Fund will be discontinued once aforesaid switch transaction are carried out.

In view of the above, relevant changes will be carried out in the SID and KIM of the abovementioned

All other features and terms & conditions of SID and KIM of the abovementioned Schemes shall remain unchanged.

This Notice-cum-Addendum forms an integral part of the SID and KIM issued for the Schemes read with the Addenda issued thereunder.

For Aditya Birla Sun Life AMC Limited

(Investment Manager for Aditya Birla Sun Life Mutual Fund) Sd/-

Authorised Signatory

Place: Mumbai Date: December 23, 2021

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.



Samvardhana Motherson International Limited

नोंदणीकत कार्यालय: यनिट ७०५. सी विंग, वन बीकेसी, जी ब्लॉक, वांदे-कर्ला संकल, मुंबई-४०० ०५१. दूर. : +९१-१२०-६६७९५०० ईमेल : smil@motherson.com, वेबसाईट : www.smil.co.in सीआयएन: यु७४९००एमएच२००४पीएलसी२८७०११

संयुक्त जाहीर सूचना

ही सूचना समवर्धना मदरसन इंटरनॅशनल लिमिटेड **(''एसएएमआयएल'')** व मदरसन सुमी सिस्टीम्स लिमिटेड (''**एसएसएसएल'**') यांच्याकडून संयुक्तपणे जारी करण्यांत येत आहे

रसएएमआयएल ही एक पब्लिक कंपनी सीआयएन–य७४९००एमएच२००४पीएलसी२८७०११ धारक कंपनी अधिनियम, १९५६ अंतर्गत ९ डिसेंबर, २००४ रोजी स्थापन झाली आणि तीचे नोंदणीकृत कार्यालय आहे- युनिट ७०५, सी विंग, वन बीकेसी, जी ब्लॉक, वांद्रे-कुर्ला संकुल, मुंबई-४०० ०५१. ७ मार्च, २०१७ दिनांकित संदर्भ क्रमांक एन-१३०२१६८ धारक नोंदणी प्रमाणपत्राद्वारे (जे ११ सप्टेंबर, २०१४ दिनांकित नोंदणी क्रमांक एन-१४.०३३०९ च्या प्रमाणपत्राच्या बदल्यांत जारी केलेले). **(''नोंदणी** प्रमाणपत्र'') एक नॉन डिपॉझिट टेकिंग कोर इन्व्हेस्टमेंट कंपनी ("सीआयसी") चा व्यवसाय करण्यासाठी रिझर्व्ह बँक ऑफ इंडिया ॲक्ट. १९३४ च्या कलम ४५-IA अन्वये एसएएमआयएल ची नोदंणी रिझर्व्ह बँक ऑफ इंडिया ("आरबीआय") कडे झाली आहे. नोंदणी प्रमाणपत्रानुसार रमएसएसएल सह एसएएमआयएल ही जाहीर सूचना जारी करत आहे.

रमएसएसएल ही सीआयएन: एल३४३००एमएच१९८६पीएलसी२८४५१० धारक कंपनी अधिनियम . १९५६ अंतर्गत १९ डिसेंबर, १९८६ रोजी स्थापित एक पब्लिक सूचीबद्ध कंपनी आहे आणि तिचे नोंदणीकृत कार्यालय आहे- युनिट ७०५, सी विंग, वन बीकेसी, जी ब्लॉक, वांद्रे-कुर्ला संकुल, मुंबई-४०० ०५९. मएसएसएलचे समभाग बीएसई लिमिटेड आणि नॅशनल स्टॉक एक्सचेंज ऑफ इंडिया लिमिटेड वर सूचीबद्ध आहेत. आज मितीस, एसएसएसएल च्या समभाग भांडवलाचा ३३.३४% वाटा एसएएमआयएल ने धारण केला आहे

प्रस्तावित देवाणघेवाण

प्रविणा के. शाह

एसएएमआयएल, एमएसएसएल व मदरसन सुमी वायरींग इंडिया लिमिटेड, एमएसएसएल ची एक संपूर्ण मालकीची उपकंपनी **(''एमएसडब्ल्युआयएल'')** व त्यांचे संबंधित भागधारक आणि धनको हे एकत्रीकरण आणि व्यवस्थेच्या एका संयुक्त योजनेचे **(''योजना'')** पक्षकार आहेत जी अन्य-गोष्टींबरोब ढोबळमानाने पुढील बाबी प्रस्तावित करते:

(बी) निर्णायक एमएसएसएल मध्ये कंपनीचे विलिनिकरण (टप्पा (ए) पूर्ण झाल्यानंतर) (ह्या टप्पा (बी) ला परिणाम स्वरूप आल्यावर तयार झालेल्या निर्णायक एमएसएसएल चा हस्तांतर उल्लेख ''नवी **एसएएमआयएल''**) असा केला जाईल.

योजनेनुसार एमएसएसएल शी सब मध्ये एसएएमआयएल चे विलिनिकरण झाल्यानंतर एसएएमआयएल न तिच्या उपकंपन्या व संयुक्त उपक्रम कंपन्यांमध्ये धारण केलेल्या सर्व गृंतवणुकांपुरते मर्यादित न राहता त्यासह एसएएमआयएल च्या सर्व मत्ता आणि दायित्वे नव्या एसएएमआयएल कडे हस्तांतरित होतील आणि समापन न होता एसएएमआयएल चे विसर्जन होईल. विलिनिकरण प्रभावी झाल्यानुसार नवी एसएएमआयएल कडून संबंधित रेकॉर्ड डेट रोजीस योजने मध्ये मांडलेल्या विलिनिकरण भाग अदलाबदल गणोत्तरा ना एसएएमआयएल च्या भागधारकांना शेअर्स जारी केले जातील आणि असे जारी केल्या बरोबर . एसएएमआयएल मध्ये भागधारकांनी धारण केलेले शेअर्स रद्द ठरतील. पुढे, योजनेच्या अनुषंगाने आणि प्रयोज्य कायद्यांतर्गत घाळून दिलेल्या प्रक्रियेच्या अधीन नव्या एसएएमआयएलचे पुनर्नामकरण ''समवर्धन नदरसर इंटरनॅशनल लिमिटेड'' असे होईल. पुढे, एमएसएसएल मध्ये आणि सह एसएएमआयएल चे विलिनिकरण झाल्यावर, योजना परिणाम स्वरूप झाल्या परिणामी, निर्णायक मंडळ म्हणजेच नवी एसएएमआयएल ही प्रभावी तागवे रोजीस एक सीआयसी किंवा एनबीएफसी नसेल

योजनेच्या संबंधात कोणतेही स्पष्टीकरण हवे असल्यास एसएएमआयएल च्या नोंद्रणीकत कार्यालयांत श्रीमती पूजा मेहरा, कंपनी सेक्रेटरींना उद्देशन लिलावे किंवा <<u>smil(gimotherson.com</u>> वर ईमेल ने संपर्क साधावा. योजने संबंधातील सर्व दस्तावेजांसह ह्या सूचेची एक प्रत एसएएमआयएलची वेबसाईट <<u>www.smil.co.in</u>> वर उपलब्ध आहेत.

मदरसन समी सिस्टीम्स लिमिटेड साठी

श्री. आलोक गोएल

समवर्धन महरसन इंटरनॅशनल लिमिटेड साठी

श्रीम. पजा मेहरा

दिनांकः २३ डिसेंबर, २०२१

नवीन पनवेल शाखा मे रावरिया सिटी तळ मजला प्लॉट क्र ८/ए बैंक ऑफ इंडिया BOI सेक्टर १८, नवीन पनवेल, जि. रायगड=४१०२०६ दू. क्र : ०२२ २७४८ ३५३०, २७४५ ५१९४ Relationship beyond banking र्डमेल आयडी: NewPanvel.Raigad@bankofindia.co.ir

दिनांक : २०.१२.२०२१

कञ्जा सूचना परिशिष्ट IV नियम - ८(१)पहा (स्थावर मिळकत) न्याअर्थी. निम्नस्वाक्षरीकार **बँक ऑफ इंडिया** चे **प्राधिकत अधिकारी** या नात्याने सिक्यरिटायझेशन ॲड

रेकन्स्ट्रक्शन ऑफ फायनान्शिअल ॲसेटर्स् ॲड एन्फोर्समेंट ऑफ सिक्युरिटी इंटरेस्ट ॲक्ट ९ (ॲक्ट), २००२ आणि कलम १३(२) सहवाचता सिक्युरिटी इंटरेस्ट (एन्फोर्समेंट) रूल्स, २००२ च्या नियमाअन्वये प्राप्त अधिकारांचा वापर करून दिनांक ०५.०४.२०२१ रोजी मागणी सचना जारी करून कर्जदार/हमीदार **मे. श्री राधे** इंटरप्राईजेस प्रोप-श्री निरज सुरेश रॉय आणि श्री. निरज सुरेश रॉय यांस सूचनेतील एकुण नमूद रक्कम रु . ९२८९०७७.०९/- (रु. ब्यान्नव लाख आणि एक्याऐंशी हजार सत्त्याहत्तर रुपये आणि नऊ पैसे **त्यावरील पुढील न लावलेले व्याज)** ची परतफेड सदर सूचना प्राप्तीच्या ६० दिवसांत करण्यात सांगितले होते येथे वरील नमूद कर्जदार आणि हमीदार रकमेची परतफेड करण्यास कर्जदार असमर्थ ठरल्याने, विशेषत: येथे वरील नमूद कर्जेदार आणि हमीदार आणि सर्वसामान्य जनतेस याद्वारे सूचना देण्यात येते की, निम्नस्वाक्षरीकारांनी खाली वर्णन करण्यात आलेल्या मिळकतीचा सिक्युरिटी (एन्फोर्समेंट) रूल्स, २००२ च्या नियम ८ सहवाचता सदर ॲक्टचे कलम १३ चे उप-कलम (४) अन्वये त्यांना प्राप्त अधिकारांचा वापर करुन **२० डिसेंबर, दो**न हजार एकवीस (२०२१) रोजी प्रत्यक्ष कब्जा घेतला आहे.

. विशेषत: येथे वरील नमूद कर्जदार आणि हमीदार आणि सर्वसामान्य जनतेस याद्वारे इशारा देण्यात येतो की, सदर मेळकतीशी कोणताही व्यवहार करू नये आणि सदर मिळकतीशी करण्यात आलेला कोणताही व्यवहार हा **बँक** ऑफ इंडियाकरिता एकूण रक्कम रु. ९२८१०७७.०९/- (रु. ब्यान्नव लाख आणि एक्याऐंशी हजार **ात्त्याहत्तर रुपये आणि नऊ पैसे)** सह वरील सदर रकमेवरील सांपार्श्विक दराने पुढील व्याज आणि पूण देयापर्यंतचे त्यावरील आनुषांगिक खर्च, परिव्यय, प्रभार इ. च्या भाराअधीन राहील.

स्थावर मिळकतीचे वर्णन

थ्री. निरज सुरेश रॉय यांच्या नावातील फ्लॅट क्र - ११०५, ११वा मजला, बी विंग, बालाजी अंगण सीएचएस लि, प्लॉट क्र. ३११, ३६६, ३६७, ३७०, ३६७, ३६९ गाव- पनवेल, ता-पनवेल, जि-रायगड येथील मिळकतीचे ते सर्व भाग आणि विभाग

दिनांक : २०/१२/२०२१ ठिकाण: नवीन पनवेल प्राधिकृत अधिकारी

> प्रपत्र क्र. २३ (रेग्युलेशन-२०(३))

परि . १३

कर्ज वसुली न्यायाधिकरण क्र. १ मुंबई समक्ष

भारत सरकार वित्तीय मंत्रालय, वित्तीय सेवा विभाग एमटीएनएल भवन, २रा मजला, टेलिफोन भवन, स्ट्रॅन्ड रोड, कुलाबा मार्केट,

> मुंबई-४०० ००५ ओए क्र: ४३२/२०२१ आयडीबीआय बँक लि

विरुद्ध बेटर व्हॅल्य लिझिंग ॲन्ड फायनान्स लि.आणि अन्य

ज्याअर्थी वरील नावाचे अर्जदार यांनी सन्माननिय न्यायाधिकरणामधील वरील उल्लेखित अर्ज दाखल केला आहे.

२. ज्याअर्थी साधारण स्वरुपात समन्सची बजावणी परिणामकारक झालेली नाही आणि ज्याअर्थी सन्माननिय न्यायाधिकरणाद्वारे पर्यायी बजावणीकरिता अर्ज संमत करण्यात आला

३. तुम्हाला सदर न्यायाधिकरणासमक्ष व्यक्तिशः वा विकलाद्वारे लेखी विवरणपत्र/म्हणणे दाखल करण्यासाठी आणि विनंतीप्रमाणे अनुतोष का मंजूर करु नये याची कारणे दर्शविण्यासाठी ०७/०१/२०२२ रोजी द.१२ वा.उपस्थित राहण्याचे निर्देश दिले आहेत. ४. सूचना घ्यावी की, कसूरवार ठरल्यास, तुमच्या अनुपस्थितीत अर्जाची सुनावणी होईल आणि निर्धारित असेल

माझ्या हस्ते आणि सदर न्यायाधिकरणाच्या शिक्क्याने ६ डिसेंबर, २०२१ रोजी दिले/जारी.

प्रतिवादी क्र.२

श्री विनायक गवांडे, ई-६, प्रथमेश को-ऑप सोसा लि व्ही.एस.रोड, प्रभादेवी,

मुंबई ४०००२५

सही / सहाय्यक प्रबंधक,डीआरटी-।, मुंबई

(This is an Advertisement for information purposes only and not for publication or distribution or release outside India and is not an Offer Document)

ANUROOP PACKAGING LII

Our Company was originally incorporated as "Anuroop Packaging Private Limited" at Mumbai as a private limited company under the Companies Act, 1956 vide Certificate of Incorporation dated October 13, 1995 bearing Corporate Identification Number 93625 issued by the Registrar of Companies, Mumbai. Subsequently, our company got converted to a public limited company pursuant to a special resolution passed by the shareholders of our company at their meeting held on May 27, 2017 and fresh Certificate of Incorporation consequent upon conversion was issue by Registrar of Companies, Mumbai on July 02, 2017 in the name of "Anuroop Packaging Limited". For details of change in name and registered office of our Company, see "General Information" on page 29 of the letter of offer dated November Registered Office: Ambiste (BK), Post Khani Tal Wada, Thane - 421303, Maharashtra, India | Tel: 022 - 49240183

Contact Person: Shah Pooja Ketan, Company Secretary and Compliance Officer Email: info@anurooppackaging.com | Website: www.anurooppackaging.com Corporate Identity Number: L25202MH1995PLC093625.

OUR PROMOTERS: MR. AMARNATH MATADIN SHARMA MR. AKASH AMARNATH SHARMA, MR. AKSHAY AMARNATH SHARMA AND AMARNATH SHARMA HUF

RIGHT ISSUE OF UPTO 30,64,400 EQUITY SHARES OF FACE VALUE OF ₹10.00 EACH ("EQUITY SHARES" OR "RIGHTS EQUITY SHARES) OF OUR COMPANY FOR CASH AT A PRICE OF ₹13.00 PER RIGHTS EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹3.00 PER RIGHTS EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING UP TO ₹ 398.37 LAKH ("THE ISSUE") ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 2 (TWO) RIGHTS EQUITY SHARES FOR EVERY 5 (FIVE) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY ON THE RECORD DATE, THAT IS FRIDAY, NOVEMBER 05, 2021 (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" ON PAGE 81 OF THE LETTER OF OFFER.

BASIS OF ALLOTMENT

The Board of Directors of our Company thanks all Investors for their response to the Issue, which opened for subscription on **Monday, November 22, 2021** and closed on **Tuesday, December 14, 2021** and the last date for On Market Renunciation of Rights Entitlements was **Wednesday, December 01, 2021**. Out of the total **152** Applications for 32,50,000 Rights Equity Shares (including 21 Applications for 6,70,000 Rights Equity Shares through R-WAP), 99 Applications for 2,48,000 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 53 for 30,02,000 Rights Equity Shares, which was 100.00% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer and the Basis of Allotment inalized on Tuesday, December 21, 2021 in consultation with BSE Limited ("BSE"), the Designated Stock Exchange and the Registrar to the Issue, the Board of Directors of the Company has, on **Tuesday, December 21, 2021**, approved the allotment of **30,02,000** fully paid up Rights Equity Shares to the successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. All valid Applications (including R-WAP Applications) after technical rejections have been considered

*Applications includes 2 partially accepted case.

. The breakup of valid applications received through ASBA and R-WAP (after technical rejections) is given below:

Applicants	Number of valid applications received	No. of Rights Equity Shares accepted and allotted against Rights Entitlement (A)	no. of Rights Equity Shares accepted and allotted against Additional Rights Equity Shares applied (B)	Shares accepted and allotted (A+B)
Eligible Equity Shareholders	41	9,98,000	1,504,000	2,502,000
Renouncees	12	4,92,000	8,000	500,000
Total	53	14,90,000	1,512,000	3,002,000

*Applications includes 2 partially accepted case. 2. Information regarding total Applications received (including ASBA and R-WAP Application):

Equity Shares Applied fo Applications Received **Equity Shares allotte** Value (₹) Number Value (₹) Shareholders 140 92.11% 2,750,000 35,698,002.00 84.60% 2.502.000 83.34% 6 500 000 00 Renouncees 12 7.89% 500.000 6.500.000.00 15.40% 500.000 16.66% 100.00% Total 152 100.00% 3,250,000 42,198,002.00 100.00% 3.002.000 39.026.000.00

Information for Allotment/refund/rejected cases: The dispatch of Allotment Advice cum Refund Intimation to the investors, as applicable, has been completed on December 22, 2021. The instructions for unblocking of funds in case of ASBA Applications were issued to SCSBs on December 22, 2021, and for refund of funds through NACH/NEFT/RTGS/direct credit were issued to ICICI Bank Limited, the Banker to the Issue, on December 22,2021. The listing application was executed with BSE on December 21, 2021. The credit of Rights Equity Shares to the respective demat accounts of the allottees in respect of Allotment in dematerialized form has been completed on December 23, 2021. For further details, see "Terms of the Issue – Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 102 of the Letter of Offer. The trading in fully paid-up Equity Shares issued in the Rights Issue shall commence on BSE under a same ISIN - INE490Z01012, as the existing equity shares, upon receipt of trading permission. The trading is expected to commence on or about December 27, 2021. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on December 22, 2021

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN THE DEMATERIALISATION FORM. DISCLAIMER CLAUSE OF SEBI: It is to be distinctly understood that the submission of the Letter of Offer to SEBI should not in any way deemed or construed that the Letter of Offer has been cleared or approved by SEBI. The investors are advised to refer to the Letter of Offer for the full text as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of SEBI" on page 76 of the Letter of Offer.

DISCLAIMER CLAUSE OF BSE (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the letter of offer. The investors are advised to refer to the Letter of Offer for the full text of the Disclaimer clause of BSE as provided in "Other Regulatory and Statutory Disclosures - Disclaimer Clause of BSE" on page 76 of the Letter of Offer. Unless otherwise specified, all capitalised terms used herein shall have the same meaning ascribed to such terms in the Letter of Offer

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY

The details of the allotment made has been hosted on the website of the Registrar to the Issue. KFin Technologies Private Limited at Website: www.kfintech.com COMPANY SECRETARY AND COMPLIANCE OFFICER REGISTRAR TO THE ISSUE

MAFINTECH **KFin Technologies Private Limited**

on page 81 of Letter of Offer

Place: Mumbai

(Formerly known as KARVY FINTECH PRIVATE LIMITED) Selenium Tower-B, Plot No-31 and 32, Financial District, Nanakramguda, Serilingampally,

Hyderabad, Rangareddi 500032, Telangana, India | **Tel**: +91 40 6716 2222 Email: Anuroop.rights@kfintech.com | Website: www.kfintech.com Investor Grievance E-mail: einward.ris@kfintech.com

Contact Person: M Murali Krishna | SEBI Registration No.: INR000000221

Thane - 421303, Maharashtra, India. | **Telephone:** 022 - 4924 0183 -mail: info@anurooppackaging.com Website: www.anurooppackaging.com Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process or R-WAP process may be addressed to the Registrar, with a copy to the SCSBs (in case of ASBA process), giving full details such as name, address

Registered Office: Ambiste (BK), Post Khani Tal Wada

Anuroop Packaging Limited

Ms. Shah Pooja Ketan

the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process)), and copy of the e-acknowledgement (in case of R-WAP process). For details on the ASBA process and R-WAP process, see "Terms of the Issue"

Ms. Shah Pooja Ketan

Disclaimer: Our Company has filed a Letter of Offer with the Securities and Exchange Board of India and the Stock Exchanges. The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, website of the Stock Exchanges where the Equity Shares are listed i.e. BSE at www.bseindia.com. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 17 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

of the Applicant, contact number(s), E-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for,

amount blocked (in case of ASBA process) or amount debited (in case of R-WAP process). ASBA Account number and the Designated Branch of the SCSBs where

Date: December 23, 2021